NCT07085104View on ClinicalTrials.gov

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

October 31, 2032

Conditions
Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory MyopathySystemic SclerosisLupus Nephritis
Interventions
GENETIC

ALLO-329

An allogeneic CAR T cell therapy targeting CD19 and CD70

DRUG

Cyclophophamide

Chemotherapy for lymphodepletion

Trial Locations (2)

27710

RECRUITING

Duke University Medical Center, Durham

08816

RECRUITING

Astera Cancer Care, East Brunswick

Sponsors
All Listed Sponsors
lead

Allogene Therapeutics

INDUSTRY